Table 2.
Cross-sectional analysis of MTX-PG concentrations and ΔDAS28 with a linear mixed model
| Week 4 | Week 8 | Week 12 | Week 24 | Week 36 | Week 52 | Week 76 | |
|---|---|---|---|---|---|---|---|
| MTX-PG1 | 0.018 (0.011) p=0.11 |
−0.003 (0.008) p=0.68 |
−0.025 (0.007)* p=0.000 |
−0.026 (0.009)* p=0.005 |
−0.013 (0.010) p=0.022 |
−0.008 (0.015) p=0.59 |
0.009 (0.013) p=0.49 |
| MTX-PG2 | 0.018 (0.016) p=0.27 |
−0.002 (0.013) p=0.86 |
−0.035 (0.011)* p=0.002 |
−0.027 (0.012)* p=0.03 |
−0.023 (0.016) p=0.15 |
−0.013 (0.017) p=0.45 |
0.021 (0.022) p=0.35 |
| MTX-PG3 | 0.019 (0.026) p=0.48 |
−0.035 (0.017)* p=0.04 |
−0.023 (0.013) p=0.07 |
−0.028 (0.014)* p=0.04 |
−0.030 (0.015)* p=0.04 |
−0.006 (0.020) p=0.76 |
0.005 (0.022) p=0.83 |
| Total MTX-PG | 0.008 (0.006) p=0.19 |
−0.003 (0.005) p=0.41 |
−0.013 (0.004)* p=0.003 |
−0.014 (0.004)* p=0.003 |
−0.009 (0.005) p=0.09 |
−0.005 (0.007) p=0.43 |
0.006 (0.007) p=0.41 |
Upper: β, SE.
Lower: p.
*p<0.05.
DAS28, Disease Activity Score for 28 joints; MTX-PG, methotrexate polyglutamate.